Category : Healthcare and Pharmaceuticals | Published at : November-2020 | Delivery Format : PDF | Status: Published | Pages : 190
The market for cervical dysplasia is expected to grow at a CAGR of around 6.9% from 2020 to 2027 and expected to reach the market value of around US$ 852.4 Mn by 2027.
Cervical Dysplasia or cervical intraepithelial neoplasia (CIN) is a precancerous condition where abnormal cell growth occurs on the surface lining of the cervix or endocervical canal, the opening between the uterus and the vagina. The condition is most common in women under age 30 but can develop at any age. It usually causes no symptoms and is most often discovered by a routine Pap test. Mild cervical dysplasia can be resolved without treatment and may only require careful observation with Pap tests every three or six months, whereas moderate-to-severe cervical dysplasia usually requires treatment to remove the abnormal cells and reduce the risk of cervical cancer. Human papillomavirus (HPV) is the primary cause of cervical dysplasia, which is an infection common in women and men. A healthy immune system can eliminate HPV and clears the infection but in some women, the infection persists and leads to cervical dysplasia. There are more than 200 different HPV viruses and around half of them are sexually transmitted. Moreover, the most common types that are strongly associated with cervical cancer are HPV 16 and HPV 18.
Market Dynamics
The growing female population that comes under the reproductive age group, raising awareness about the condition, and availability of advanced medical facilities, increasing cases of STDs, increasing vaginal infection, increasing smoking propensity, drug abuse, are some of the major factors driving the market growth. The rising prevalence of cancer coupled with the increasing number of awareness campaigns for the early diagnosis of the disease is supporting the market growth. Additionally, a report published by the WHO stated that this disease is the most common cause of HPV-associated cancer in women.
On the other hand, lack of medical facilities in the developing economies, high cost associated with the surgery, expensive drug cost, the absence of the reimbursement policies, and lack of skilled physicians are some of the factors anticipated to limit the growth to an extent throughout the forecast timeframe from 2020 to 2027.
Segment Instance
Hospitals is the leading segment by end users in the cervical dysplasia market
The hospital segment has registered a maximum revenue share (%) in 2019. The segment is also projected to maintain its dominance over the forecast period from 2020 to 2027. The presence of efficient products and professionals who can effectively use these test equipment for the treatment is supporting the segmental market value. The increasing investment in the hospitals for the development of technologically advanced infrastructure for the treatment of patients is boosting the market growth.
North America accounted for the maximum revenue share (%) in the Cervical Dysplasia market
In 2019, North America is leading the market with maximum revenue share (%) in the global market. The well-established healthcare infrastructure and emerging economies of the region are accelerating the regional market value. The presence of major players in the region is further bolstering the regional market value. Additionally, the ongoing research and development activities by the major players of the region are supporting the regional market growth.
Key Market Players
The players profiled in the report include Abbott Laboratories (US), Becton, Dickinson, and Company (US), F. Hoffmann La-Roche Ltd. (Switzerland), GlaxoSmithKline Plc. (UK), Hologic, Inc. (US), OncoHealth Corporation, Qiagen N.V. (Germany), Quest Diagnostics, Inc. (US), and others. The major market players were involved in mergers and acquisitions, partnerships & collaborations, and new product development for the expansion of market share (%).
Market Segmentation
Market By Treatment Type
Surgery
Chemotherapy
Therapeutic HPV Vaccines
Radiation Therapy
Other Treatment Types
Market By End Users
Hospitals
Diagnostic Centers
Ambulatory Surgery Centers
Specialty Clinics
Research & Academic Institutes
Market By Geography
North America
- U.S.
- Canada
Europe
- U.K.
- Germany
- France
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
Frequently Asked Questions
The market for cervical dysplasia is expected to reach a market value of around US$ 852.4 Mn by 2027.
The cervical dysplasia market is expected to grow at a CAGR of around 6.9% from 2020 to 2027.
Hospitals is the leading segment by end users in the cervical dysplasia market
The growing female population that comes under the reproductive age group, rising awareness about the condition, and availability of the advanced medical facilities, increasing cases of STDs, increasing vaginal infection, increasing smoking propensity, drug abuse, rising prevalence of cancer, and an increasing number of awareness campaigns for the early diagnosis of the disease are some of the factors driving the market growth.
Abbott Laboratories (US), Becton, Dickinson, and Company (US), F. Hoffmann La-Roche Ltd. (Switzerland), GlaxoSmithKline Plc. (UK), Hologic, Inc. (US), OncoHealth Corporation, Qiagen N.V. (Germany), and Quest Diagnostics, Inc. (US), are some of the prominent players in the market.
North America held the highest market share in the cervical dysplasia market
The report provides insights on global cervical dysplasia market segment by product, application, and major geographic regions.
